News Image

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.

By Mill Chart

Last update: Mar 14, 2024

In this article, we'll take a closer look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as a potential candidate for growth investing. While it's important for investors to conduct their own research, HALOZYME THERAPEUTICS INC has piqued our interest by appearing on our strong growth and breakout radar. Let's explore further.

What does the Growth looks like for NASDAQ:HALO

ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:HALO scores a 9 out of 10:

  • The Earnings Per Share has grown by an impressive 25.23% over the past year.
  • HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 45.64% yearly.
  • The Revenue has grown by 25.59% in the past year. This is a very strong growth!
  • The Revenue has been growing by 40.42% on average over the past years. This is a very strong growth!
  • Based on estimates for the next years, HALO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.73% on average per year.
  • The Revenue is expected to grow by 11.91% on average over the next years. This is quite good.

Health Analysis for NASDAQ:HALO

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:HALO scores a 7 out of 10:

  • An Altman-Z score of 3.55 indicates that HALO is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of HALO (3.55) is better than 73.06% of its industry peers.
  • HALO has a Debt to FCF ratio of 4.02. This is amongst the best in the industry. HALO outperforms 94.61% of its industry peers.
  • A Current Ratio of 6.64 indicates that HALO has no problem at all paying its short term obligations.
  • The Current ratio of HALO (6.64) is better than 62.79% of its industry peers.
  • HALO has a Quick Ratio of 5.50. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.

How do we evaluate the Profitability for NASDAQ:HALO?

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:HALO, the assigned 7 is noteworthy for profitability:

  • With an excellent Return On Assets value of 16.25%, HALO belongs to the best of the industry, outperforming 98.82% of the companies in the same industry.
  • HALO's Return On Equity of 335.99% is amongst the best of the industry. HALO outperforms 100.00% of its industry peers.
  • HALO's Return On Invested Capital of 17.00% is amongst the best of the industry. HALO outperforms 98.65% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HALO is above the industry average of 13.47%.
  • The Profit Margin of HALO (33.96%) is better than 98.82% of its industry peers.
  • HALO's Operating Margin of 41.02% is amongst the best of the industry. HALO outperforms 99.16% of its industry peers.
  • HALO's Gross Margin of 76.82% is amongst the best of the industry. HALO outperforms 85.69% of its industry peers.

Looking at the Setup

Next to the Technical Rating, the Setup Rating of a stock determines to which extend the stock is consolidating. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. For NASDAQ:HALO this score is currently 8:

HALO has an excellent technical rating and also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. A pullback is taking place, which may present a nice opportunity for an entry. There is very little resistance above the current price. There is a support zone below the current price at 41.34, a Stop Loss order could be placed below this zone. Another positive sign is the recent Pocket Pivot signal.

Every day, new Strong Growth stocks can be found on ChartMill in our Strong Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of HALO

Our latest full technical report of HALO contains the most current technical analsysis.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/30/2024, 8:30:50 AM)

42.62

-0.14 (-0.33%)

HALO News

News Imagea day ago - ChartmillNASDAQ:HALO is probably undervalued for the fundamentals it is displaying.

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

News Image9 days ago - Halozyme Therapeutics, Inc.Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee...

News Image13 days ago - Market News VideoHALO July 19th Options Begin Trading
News Image14 days ago - Investor's Business DailyHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating

On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

News Image16 days ago - Investor's Business DailyCatalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating

On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.

News Image16 days ago - ChartmillWhile growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...

News Image21 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in May 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

News Image22 days ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present...

News Image23 days ago - InvestorPlaceHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image23 days ago - BusinessInsiderHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Halozyme Therapeutics (NASDAQ:HALO) just reported results for the first quarter...

HALO Links
Follow us for more